Literature DB >> 22544195

Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso.

Antoine Somda1, Lassana Sangare, Monique Soro, Saydou Yameogo, Babou Bazie, Françoise Bigirimana, Silvia Bertagnolio, Martine Peeters, Fatima Mouacha, Ana Maria Rivera, Michael R Jordan, Marie-Joseph Sanou.   

Abstract

Burkina Faso began rapid antiretroviral therapy (ART) scale-up in 2003 and by December 2009, 26,448 individuals were on treatment. With rapid scale-up of ART, some degree of human immunodeficiency virus transmitted drug resistance (TDR) is inevitable. Following World Health Organization methods, between June 2008 and July 2009, Burkina Faso assessed TDR in primigravid pregnant women aged <25 years attending antenatal care clinics in Ouagadougou, Burkina Faso. TDR was classified as moderate (5%-15%) for both nucleoside reverse-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors. The observed moderate TDR in Ouagadougou is a cause for concern and calls for closer monitoring of Burkina Faso's ART program.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544195      PMCID: PMC3338307          DOI: 10.1093/cid/cir988

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon.

Authors:  Laurence Vergne; Serge Diagbouga; Charles Kouanfack; Avelin Aghokeng; Christelle Butel; Christian Laurent; Nathalie Noumssi; Michêle Tardy; Adrien Sawadogo; Joseph Drabo; Hervé Hien; Léopold Zekeng; Eric Delaporte; Martine Peeters
Journal:  Antivir Ther       Date:  2006

2.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment.

Authors:  Diane E Bennett; Mark Myatt; Silvia Bertagnolio; Donald Sutherland; Charles F Gilks
Journal:  Antivir Ther       Date:  2008

3.  World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.

Authors:  Michael R Jordan; Diane E Bennett; Silvia Bertagnolio; Charles F Gilks; Donald Sutherland
Journal:  Antivir Ther       Date:  2008

4.  The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.

Authors:  Diane E Bennett; Silvia Bertagnolio; Donald Sutherland; Charles F Gilks
Journal:  Antivir Ther       Date:  2008

5.  Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.

Authors:  Ahidjo Ayouba; Truong T X Lien; Janin Nouhin; Laurence Vergne; Avelin Fobang Aghokeng; Nicole Ngo-Giang-Huong; Halimatou Diop; Coumba Touré Kane; Diane Valéa; François Rouet; Dominique Joulia-Ekaza; Thomas D'Aquin Toni; Eric Nerrienet; Eitel Mpoudi Ngole; Eric Delaporte; Dominique Costagliola; Martine Peeters; Marie-Laure Chaix
Journal:  AIDS Res Hum Retroviruses       Date:  2009-11       Impact factor: 2.205

Review 6.  Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.

Authors:  G J Hanna; R T D'Aquila
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

7.  Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.

Authors:  Geofrey R Somi; Tabitha Kibuka; Karidja Diallo; Tulli Tuhuma; Diane E Bennett; Chunfu Yang; Charles Kagoma; Eligius F Lyamuya; Roland O Swai; Sidibe Kassim
Journal:  Antivir Ther       Date:  2008

8.  Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi.

Authors:  Kelita Kamoto; John Aberle-Grasse
Journal:  Antivir Ther       Date:  2008

9.  The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.

Authors:  V DeGruttola; L Dix; R D'Aquila; D Holder; A Phillips; M Ait-Khaled; J Baxter; P Clevenbergh; S Hammer; R Harrigan; D Katzenstein; R Lanier; M Miller; M Para; S Yerly; A Zolopa; J Murray; A Patick; V Miller; S Castillo; L Pedneault; J Mellors
Journal:  Antivir Ther       Date:  2000-03

10.  The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Tommy F Liu; Soo-Yon Rhee; Mark Kiuchi; Stephane Hue; Deenan Pillay; Robert W Shafer
Journal:  Bioinformatics       Date:  2009-03-20       Impact factor: 6.937

View more
  2 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Prevalence of HIV-1 pretreatment drug resistance among treatment naïve pregnant women in Bissau, Guinea Bissau.

Authors:  Sten Wilhelmson; Fredrik Månsson; Jacob Lopatko Lindman; Ansu Biai; Joakim Esbjörnsson; Hans Norrgren; Marianne Jansson; Patrik Medstrand
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.